Metformin is associated with improved survival in endometrial cancer

Ko, Emily; Walter, Paige; Jackson, Amanda; Clark, Leslie H.; Franasiak, Jason M.; Bolac, C.; Havrilesky, Laura J.; Secord, Angeles Alvarez; Moore, Dominic T.; Gehrig, Paola A.; Bae‐Jump, Victoria L.

doi:10.1016/j.ygyno.2013.11.021

Cited by 145 publications

(125 citation statements)

References 30 publications

Supporting

Mentioning

117

Contrasting

Order By: Relevance

“…AMPK, adenosine monophosphate-activated protein kinase; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; PR, progesterone receptor; MPA, medroxyprogesterone acetate; S6K, S6 kinase. (43,49,50,(55)(56)(57)(58). The effect in cervical cancer has not been examined in clinical studies thus far, although efficacy of metformin in vitro has been observed (61).…”

Section: Resultsmentioning

confidence: 99%

“…RFS in the non-metformin group was reduced by 1.8-fold (95% CI, 1.1-2.9; P= 0.02), while OS was reduced by 2.3-fold (95% CI, 1.3-4.2; P= 0.005). However, there was no association between metformin treatment and time to recurrence, indicating that metformin has a survival benefit for mortality, but does not prolong the time to recurrence, for reasons that remain to be elucidated (43). Thus, additional studies are required to confirm if adjuvant therapy with metformin is effective for patients exhibiting endometrial cancer, regardless of the complication of diabetes.…”

Section: Antitumor Effect Of Metformin In Endometrial Cancermentioning

confidence: 98%

“…Two studies have demonstrated the efficacy of metformin for the treatment of endometrial cancer (43,62). In these studies, the RR of treatment with metformin was 0.49 (95% CI, 0.32-0.73; P= 0.001), with no difference in the results in meta-analysis and no heterogeneity (I 2 = 0%) (58).…”

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 98%

“…Ko et al (43) investigated the efficacy of metformin in 1,495 patients exhibiting endometrial cancer, including 363 (24%) patients with diabetes. Patients treated with metformin (54% of diabetic patients in the study) demonstrated significantly improved recurrence-free survival (RFS) and overall survival (OS) rates in comparison with patients who were not administered metformin.…”

Section: Antitumor Effect Of Metformin In Endometrial Cancermentioning

confidence: 99%

See 3 more Smart Citations

Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning

et al. 2016

View full text Add to dashboard Cite

Abstract. Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Antitumor Effect Of Metformin In Endometrial Cancermentioning

confidence: 98%

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 98%

Section: Antitumor Effect Of Metformin In Endometrial Cancermentioning

confidence: 99%

See 2 more Smart Citations

Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For example, recent evidence suggests that higher aspirin intake is associated with reduced risk of myeloma. 104 Metformin has demonstrated improvements in survival in diabetic patients with other malignancies, [105][106][107] and would be a logical candidate for chemoprevention of myeloma as well.…”

Section: Impact Of Obesity On Myeloma Treatment and Prognosismentioning

confidence: 99%

The skinny on obesity and plasma cell myeloma: a review of the literature

Carson

Bates

Tomasson

2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Despite tremendous advances in treatments for myeloma in the past decade, the disease remains incurable in the majority of patients. Here, we review recent data demonstrating an association between obesity and increased risk of myeloma development. This may be due to the pro-inflammatory cytokine profile caused by obesity. Currently, there are no screening or prevention strategies for myeloma, but we propose that obesity-associated inflammatory pathways, or obesity itself, may be amenable to intervention, thereby preventing the transition from pre-malignancy to myeloma. In addition, we suggest that the morbidity, mortality and the significant costs associated with myeloma treatment could be reduced by addressing modifiable risk factors, and that research efforts should explore this novel hypothesis. INTRODUCTIONOver the past several decades, the prevalence of obesity has increased markedly in the United States. 1 Today, two-thirds of the adult population in the United States is overweight (defined as body mass index (BMI) = 25 kg/m 2 and o 30 kg/m 2 ) or obese (BMI 30 kg/m 2 ). 2 A BMI greater than 25 kg/m 2 is associated with increased all-cause mortality. 3,4 This increased risk exists even in the absence of typically-measured metabolic abnormalities, suggesting that there is no 'benign phenotype' for obesity. 5 A substantial number of these premature obesity-related deaths is due to cancer. 6,7 Although the common solid tumor malignancies have received much attention, data from case-control and prospectively followed cohort studies have also demonstrated a positive association between obesity and plasma cell myeloma incidence and death. 7,8

show abstract